Pfizer has received federal approval to market Celebrex, its Cox-2 inhibiting painkiller, as a treatment for Juvenile Rheumatoid Arthritis (JRA). JRA affects tens of thousands of children, and other treatments have seen limited success or resulted in severe side effects.The decision comes after FDA advisers recommended Nov. 29 the drug as an effective but not necessarily safe treatment for the...